HC Wainwright Boosts Checkpoint Therapeutics (NASDAQ:CKPT) Price Target to $15.00

Checkpoint Therapeutics (NASDAQ:CKPT) had its target price hoisted by HC Wainwright from $11.00 to $15.00 in a report issued on Wednesday, May 1st, The Fly reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts have also commented on the company. Zacks Investment Research upgraded Checkpoint Therapeutics from a hold rating to a buy rating and set a $3.50 price objective on the stock in a research report on Wednesday, March 20th. ValuEngine lowered Checkpoint Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 2nd.

CKPT stock traded down $0.25 during midday trading on Wednesday, reaching $4.38. 94,176 shares of the company’s stock traded hands, compared to its average volume of 67,157. The stock has a market capitalization of $169.24 million, a price-to-earnings ratio of -3.45 and a beta of 4.51. Checkpoint Therapeutics has a 1-year low of $1.50 and a 1-year high of $5.20.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.09. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. Checkpoint Therapeutics had a negative return on equity of 211.99% and a negative net margin of 952.83%. As a group, equities research analysts forecast that Checkpoint Therapeutics will post -0.64 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Checkpoint Therapeutics by 8.2% in the 1st quarter. Renaissance Technologies LLC now owns 124,404 shares of the company’s stock worth $356,000 after purchasing an additional 9,400 shares during the last quarter. Shepherd Kaplan Krochuk LLC boosted its position in shares of Checkpoint Therapeutics by 25.0% in the 4th quarter. Shepherd Kaplan Krochuk LLC now owns 50,000 shares of the company’s stock worth $91,000 after purchasing an additional 10,000 shares during the last quarter. Jefferies Group LLC bought a new position in shares of Checkpoint Therapeutics in the 1st quarter worth $36,000. Charles Schwab Investment Management Inc. bought a new position in shares of Checkpoint Therapeutics in the 1st quarter worth $48,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Checkpoint Therapeutics in the 4th quarter worth $36,000. Institutional investors and hedge funds own 8.34% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.

Recommended Story: FAANG Stocks

The Fly

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.